Gilead Sciences (GILD) : New Century Investment Management Inc scooped up 93 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 26, 2016. The investment management firm now holds a total of 58,128 shares of Gilead Sciences which is valued at $5,127,471.Gilead Sciences makes up approximately 2.47% of New Century Investment Management Inc’s portfolio.
Gilead Sciences opened for trading at $88.7 and hit $89.45 on the upside on Monday, eventually ending the session at $89, with a gain of 0.90% or 0.79 points. The heightened volatility saw the trading volume jump to 1,35,24,049 shares. Company has a market cap of $121,649 M.
Other Hedge Funds, Including , Parsons Capital Management Incri reduced its stake in GILD by selling 98 shares or 0.53% in the most recent quarter. The Hedge Fund company now holds 18,415 shares of GILD which is valued at $1,624,387. Gilead Sciences makes up approx 0.22% of Parsons Capital Management Incri’s portfolio.Private Wealth Partners boosted its stake in GILD in the latest quarter, The investment management firm added 12,350 additional shares and now holds a total of 61,375 shares of Gilead Sciences which is valued at $5,413,889. Gilead Sciences makes up approx 1.29% of Private Wealth Partners’s portfolio.Hudson Valley Investment Advisors Inc Adv boosted its stake in GILD in the latest quarter, The investment management firm added 2,895 additional shares and now holds a total of 16,400 shares of Gilead Sciences which is valued at $1,446,644. Gilead Sciences makes up approx 0.47% of Hudson Valley Investment Advisors Inc Adv’s portfolio. Oliver Luxxe Assets sold out all of its stake in GILD during the most recent quarter. The investment firm sold 4,821 shares of GILD which is valued $491,405.Sit Investment Associates Inc boosted its stake in GILD in the latest quarter, The investment management firm added 85 additional shares and now holds a total of 555,185 shares of Gilead Sciences which is valued at $54,569,134. Gilead Sciences makes up approx 0.99% of Sit Investment Associates Inc’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.